Europe GLP-1 Receptor Agonist Market Report Scope & Overview:

Europe GLP-1 Receptor Agonist Market was valued at USD 14.54 Billion in 2025 and is expected to reach USD 58.84 Billion by 2035, growing at a CAGR of 15.00% from 2026-2035.

The Europe GLP-1 Receptor Agonist Market continues to grow at a steady pace, supported more by payer decisions rather than end consumer needs. The national health technology assessment agencies in Germany, United Kingdom, and France continue to expand their coverage of incretin-based therapy for diabetes management, albeit more selectively for the treatment of obesity. Novo Nordisk’s Kalundborg manufacturing plant in Denmark plays an integral role in both regional and global manufacturing, and increased investments into its manufacturing capabilities have eased the shortages that constrained volumes until 2023–2024. Rising clinical guideline support for GLP-1 therapy in cardiometabolic risk reduction is strengthening the case for broader public funding, while growing private-pay demand for obesity treatment in markets with limited public coverage is emerging as a parallel growth channel.

The European Medicines Agency’s pharmacovigilance committee continued monitoring GLP-1 safety signals through 2025, reinforcing regulators’ emphasis on structured post-marketing surveillance as prescribing volumes rise across the region. North America held approximately 45.00% share of the global GLP-1 Receptor Agonist Market in 2025, while Asia Pacific is forecast to post the fastest regional CAGR of 26.50% from 2026-2035, both outpacing Europe’s growth rate.

Germany GLP-1 Receptor Agonist Market Outlook

Germany GLP-1 Receptor Agonist Market was valued at USD 3.20 Billion in 2025 and is expected to reach USD 11.89 Billion by 2035, growing at a CAGR of 14.05% from 2026-2035.

The Germany GLP-1 Receptor Agonist Market is still the biggest in Europe due to the presence of health insurance coverage in statutory benefits for diabetes applications, the significant number of people suffering from diabetes, and an established pharmaceutical distribution network. The evaluation of incretin drugs is being carried out by Gemeinsamer Bundesausschuss and IQWiG. Obese people do not have as much coverage as patients with diabetes, but it is being sought after. Novo Nordisk and Eli Lilly both maintain strong commercial infrastructure in the country, supporting consistent product availability across hospital and retail pharmacy channels, while private supplementary insurance is increasingly used to bridge gaps in obesity treatment funding.

Germany’s Federal Joint Committee confirmed in 2025 that obesity-indicated GLP-1 therapies would continue to require case-by-case statutory justification, keeping private-pay channels an important near-term growth driver for German obesity demand. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

Europe GLP-1 Receptor Agonist Market Segment Analysis

• By Product, Ozempic dominates the Europe GLP-1 Receptor Agonist Market with 35.80% share in 2025; Zepbound is expected to grow at the fastest CAGR of 16.90% from 2026–2035.

• By Application, Type 2 Diabetes Mellitus dominates the Europe GLP-1 Receptor Agonist Market with 58.40% share in 2025; Obesity is expected to grow at the fastest CAGR of 17.70% from 2026–2035.

• By Route of Administration, Parenteral dominates the Europe GLP-1 Receptor Agonist Market with 71.20% share in 2025; Oral is expected to grow at the fastest CAGR of 18.80% from 2026–2035.

• By Distribution Channel, Retail Pharmacies dominate the Europe GLP-1 Receptor Agonist Market with 48.70% share in 2025; Online Pharmacies are expected to grow at the fastest CAGR of 17.90% from 2026–2035.

By Product, Ozempic Dominates the Europe GLP-1 Receptor Agonist Market, Zepbound Grows Fastest

Ozempic holds the largest European share given its long-standing diabetes approval, broad statutory insurance coverage across member states, and deep physician familiarity built over multiple reimbursement cycles since its initial European launch. Novo Nordisk’s Kalundborg manufacturing base and established commercial infrastructure across Germany, France, and the United Kingdom have reinforced Ozempic’s lead even as newer tirzepatide-based competitors expand their own national reimbursement filings across the region. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Zepbound is forecast to grow fastest as Eli Lilly expands its European launch footprint and pursues additional national reimbursement approvals, gradually converting the region’s large untreated obesity population into funded prescriptions. Progress on Mounjaro and Zepbound reimbursement discussions with Germany’s Gemeinsamer Bundesausschuss and the NHS in the United Kingdom is expected to accelerate this growth further as additional member states expand obesity-indication coverage through the forecast period. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

By Application, Type 2 Diabetes Mellitus Dominates the Europe GLP-1 Receptor Agonist Market, Obesity Grows Fastest

Diabetes management dominates the European market because statutory health insurance systems have reimbursed incretin therapy for this indication far longer than for obesity, concentrating volumes in diabetes care across most member states. Physician familiarity with incretin therapy as an established glycemic-control tool, combined with long-standing national formulary placement, continues to anchor diabetes care as the dominant application across both hospital specialist and general-practice settings throughout the region. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Obesity is set to grow fastest as select national health technology assessment bodies gradually expand coverage criteria and clinical guidelines increasingly recognize incretin therapy’s cardiometabolic benefits beyond glycemic control alone. The NHS’s phased obesity-treatment rollout in the United Kingdom and growing private-pay demand in markets with limited statutory coverage are both accelerating patient conversion from diagnosis to active obesity therapy across Europe. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

By Route of Administration, Parenteral Dominates the Europe GLP-1 Receptor Agonist Market, Oral Grows Fastest

Injectable weekly therapy remains dominant given its established reimbursement pathway and the long prescribing history across both hospital specialist and general-practice settings throughout Europe. Established manufacturing scale at Novo Nordisk’s Danish sites, broad statutory insurance coverage, and years of patient familiarity with self-administered weekly injections continue to reinforce the channel’s lead across most member states. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Oral GLP-1 therapy is growing fastest as expanded Rybelsus marketing and anticipated orforglipron approval target primary-care prescribers who want a simpler, needle-free starting option for diabetes patients across the region. Lower per-dose manufacturing complexity and growing physician comfort recommending oral incretin therapy as a first step are expected to accelerate this shift across Germany, France, and the United Kingdom through 2035. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

By Distribution Channel, Retail Pharmacies Dominate the Europe GLP-1 Receptor Agonist Market, Online Pharmacies Grow Fastest

Community retail pharmacies remain the primary dispensing channel across Europe given their regulated role in statutory insurance billing and established patient relationships for chronic therapy refills. Long-standing national pharmacy networks and continued patient preference for in-person pharmacist consultation on injection technique keep this channel central to both diabetes and obesity prescription fulfillment across most member states. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Online and licensed telepharmacy channels are growing fastest, particularly for private-pay obesity treatment in markets where statutory coverage remains limited, offering patients faster access outside traditional in-person prescribing pathways. Expanding digital pharmacy platforms in Germany, France, and the United Kingdom are reinforcing this channel’s growth, particularly among self-pay obesity patients seeking to avoid lengthy specialist referral waiting lists. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

Regional Analysis

Germany GLP-1 Receptor Agonist Market Insights

Germany dominated the Europe GLP-1 Receptor Agonist Market with the highest revenue share of about 21.87% in 2025, supported by its large diagnosed diabetic population, robust statutory health insurance system, and well-established pharmaceutical distribution network. Continued benefit assessments by the Gemeinsamer Bundesausschuss and strong commercial infrastructure from Novo Nordisk and Eli Lilly keep Germany the leading national contributor to European GLP-1 revenue. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Germany’s dense network of statutory sickness funds and well-established hospital pharmacy infrastructure continue to support consistent diabetes-indication prescription volume across the country. Growing clinical advocacy for broader obesity-indication statutory coverage, alongside rising private supplementary insurance uptake, is expected to further reinforce Germany’s leading position within the European market through the remainder of the forecast period. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

United Kingdom GLP-1 Receptor Agonist Market Insights

The United Kingdom is expected to grow at the fastest CAGR of about 18.00% from 2026–2035, supported by the National Health Service’s phased rollout of Wegovy and Mounjaro through primary care and specialist weight-management services. NICE’s expanding technology appraisals for incretin-based obesity treatment, combined with growing NHS digital weight-management pathways, are accelerating adoption across England, Scotland, and Wales faster than in any other European market. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Continued NHS investment in digital weight-management services and primary-care prescribing pathways is expected to further widen patient access across the United Kingdom through 2035. Growing clinical guideline support for earlier obesity intervention, combined with the NHS’s structured phased rollout approach, positions the United Kingdom as a template other European health systems may increasingly follow as their own budget-impact models mature. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

France GLP-1 Receptor Agonist Market Insights

The France GLP-1 Receptor Agonist Market benefits from Assurance Maladie reimbursement for diabetes indications and a growing number of specialist obesity centers evaluating incretin therapy for broader national coverage. Continued investment in hospital-based weight-management programs and growing physician advocacy for expanded statutory reimbursement are expected to support steady incremental growth across France through the remainder of the forecast period, even as obesity coverage remains more restricted than for diabetes indications nationally. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Italy GLP-1 Receptor Agonist Market Insights

The Italy GLP-1 Receptor Agonist Market is supported by AIFA-regulated regional drug budgets and a growing diabetic population, though obesity-indication funding remains more limited than in larger Western European markets. Regional variation in drug budget allocation across Italy’s twenty regions continues to create uneven patient access, though growing national clinical guideline support for incretin therapy is expected to gradually narrow this gap through 2035. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

Spain GLP-1 Receptor Agonist Market Insights

The Spain GLP-1 Receptor Agonist Market is expanding as regional health authorities gradually broaden incretin therapy access, supported by growing private insurance uptake for obesity treatment in major metropolitan areas. Continued investment in specialist endocrinology and obesity clinics across Madrid and Barcelona, combined with gradually expanding regional health service formularies, is expected to support steady growth across the country through the forecast period. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Rest of Europe GLP-1 Receptor Agonist Market Insights

The Rest of Europe GLP-1 Receptor Agonist Market, spanning Poland, Russia, and smaller Western and Nordic markets, is growing as national formularies gradually add incretin therapies and cross-border private-pay demand increases. Rising diabetes and obesity prevalence across Central and Eastern Europe, combined with gradually improving pharmaceutical distribution infrastructure, is expected to support continued incremental growth across this diverse group of markets through 2035. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

Market Dynamics

Growth Drivers: Expanding national reimbursement approvals for diabetes and gradually widening obesity coverage are increasing GLP-1 demand.

National health technology assessment bodies across Germany, the United Kingdom, and France continue to broaden statutory coverage for incretin-based diabetes therapy, while obesity reimbursement is expanding more cautiously as new cardiometabolic outcome data strengthens the clinical case for public funding. Novo Nordisk’s continued investment in Danish manufacturing capacity is resolving the regional supply constraints that limited growth through 2023-2024, and growing clinical guideline support for GLP-1 therapy in cardiovascular risk reduction is reinforcing physician confidence across both specialist and primary-care settings throughout the region. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Restraints: Restrictive obesity reimbursement criteria across most member states continue to limit broader patient access.

Most of the statutory health insurance schemes in Europe still provide reimbursement for GLP-1 treatments for diabetes only, leaving obesity management dependent on individual case approvals or self-payments. Such an approach results in disparities between member states with positive health technology assessments and strict budget impact criteria. In addition, negotiations on the price of incretin treatment further delay the process of making such treatments available to patients. As more physicians gain experience in treating patients using incretin drugs and payer discussions continue to expand, this trend will be seen throughout the rest of the forecast period.

Opportunities: Expanding NHS and national obesity-treatment pathways create significant long-term growth potential.

The National Health Service’s phased rollout of obesity-indicated GLP-1 therapy in the United Kingdom offers a template that other European health systems may increasingly follow as budget-impact models mature. Continued Danish manufacturing capacity expansion is expected to further ease supply constraints, while growing clinical evidence on cardiometabolic benefits is strengthening the case for broader statutory funding across additional member states over the forecast period. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Recent Developments:

• 2025: Novo Nordisk expanded its Kalundborg, Denmark manufacturing site to increase European and global GLP-1 supply capacity.

• 2025: The NHS in England began a phased national rollout of Wegovy through primary-care weight-management services.

• 2026: Eli Lilly progressed Mounjaro reimbursement discussions with Germany’s Gemeinsamer Bundesausschuss for expanded obesity access.

• 2025: Sanofi advanced its amlitelimab and metabolic-disease pipeline collaborations to strengthen its European cardiometabolic portfolio.

Europe GLP-1 Receptor Agonist Market Key Players are:

• Novo Nordisk A/S

• Eli Lilly and Company

• Sanofi S.A.

• AstraZeneca plc

• Boehringer Ingelheim International GmbH

• Roche Holding AG

• Novartis AG

• Bayer AG

• Merck KGaA

• GSK plc

• UCB S.A.

• Zealand Pharma A/S

• Ascendis Pharma A/S

• Teva Pharmaceutical Industries Ltd.

• Fresenius SE & Co. KGaA

• Grunenthal GmbH

• Orion Corporation

• Stada Arzneimittel AG

• Gedeon Richter Plc

• Chiesi Farmaceutici S.p.A.

Europe GLP-1 Receptor Agonist Market Report Scope: